PartnershipJun 8, 2026, 01:01 AM
Nurix & Roche Partner for Bexobrutideg; Nurix Gets $700M Upfront
AI Summary
Nurix Therapeutics announced a global collaboration with Roche to develop and commercialize bexobrutideg, a potential best-in-class oral degrader of Bruton's tyrosine kinase (BTK). Nurix will receive an upfront cash payment of $700 million and is eligible for up to $2.3 billion in potential development, regulatory, and sales milestones. The partnership includes a comprehensive clinical development plan across malignant hematology, immunology, and neurology, with shared profits and losses in the U.S. and royalties for Nurix on ex-U.S. sales.
Key Highlights
- Nurix receives $700 million upfront cash payment from Roche.
- Nurix is eligible for up to $2.3 billion in development, regulatory, and sales milestones.
- Development costs for bexobrutideg will be shared 40% by Nurix and 60% by Roche.
- Profits and losses from U.S. commercialization will be split equally between Nurix and Roche.
- Nurix will receive low- to high-teens royalties on ex-U.S. sales.
- The collaboration covers bexobrutideg, an oral BTK degrader, for malignant hematology, immunology, and neurology.
- Clinical development includes pivotal Phase 2/3 trials in CLL and Phase 2 trials in MS and CSU.
Price Impact
More from NRIX